Bagsværd, Denmark, 8 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 1 July 2019, the following transactions have been made under the programme:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 4,468,000 | 1,464,295,863 | |
1 July 2019 | 125,000 | 339.31 | 42,413,255 |
2 July 2019 | 128,000 | 342.91 | 43,892,487 |
3 July 2019 | 140,500 | 346.88 | 48,736,153 |
4 July 2019 | 135,900 | 342.54 | 46,551,012 |
5 July 2019 | 125,000 | 339.80 | 42,474,713 |
Accumulated under the programme | 5,122,400 | 1,688,363,483 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 27,465,543 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 5 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 20,298,904 B shares at an average share price of DKK 326.29 per B share equal to a transaction value of DKK 6,623,317,084.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement 40/2019
Attachment